LAURUSLABSNSEJuly 25, 2025

Laurus Labs Limited

3,082words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
July 25, 2025 To To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 The Listing Department National Stock Exchange of India Ltd., Ex
₹ 1,570
1 Corporate Overview Q1 FY 2026 4 Executive Summary • Strong performance continued in Q1; ₹ 1,570 Cr Revenues and 31% revenues growth • Attractive market opportunities favoring robust CDMO mom
31%
Q1 FY 2026 4 Executive Summary • Strong performance continued in Q1; ₹ 1,570 Cr Revenues and 31% revenues growth • Attractive market opportunities favoring robust CDMO momentum, expanding coll
₹ 389
avoring robust CDMO momentum, expanding collaboration in complex API and growth in Generics • ₹ 389 Cr EBITDA resulted in a margin of 24.8%, improving by 10.5% pts, due to Ramp up in CDMO and Operati
24.8%
g collaboration in complex API and growth in Generics • ₹ 389 Cr EBITDA resulted in a margin of 24.8%, improving by 10.5% pts, due to Ramp up in CDMO and Operating leverage • Gross margins remained s
10.5%
mplex API and growth in Generics • ₹ 389 Cr EBITDA resulted in a margin of 24.8%, improving by 10.5% pts, due to Ramp up in CDMO and Operating leverage • Gross margins remained strong at 59.4% on pos
59.4%
ng by 10.5% pts, due to Ramp up in CDMO and Operating leverage • Gross margins remained strong at 59.4% on positive product mix • Continued investment to enhance manufacturing network and customer
17%
hance manufacturing network and customer offering including specialized modalities with CAPEX at 17% of sales © 2025 Laurus Labs Ltd. Q1 - FY26 Results Presentation 25/07/2025 5 Continued recov
1.5x
ts Presentation 25/07/2025 5 Continued recovery in asset turnover levels and resilient margins 1.5x 54% (~6 Quarters) - Long lead times for Complex CDMO projects - High Capex Intensity - Hig
54%
sentation 25/07/2025 5 Continued recovery in asset turnover levels and resilient margins 1.5x 54% (~6 Quarters) - Long lead times for Complex CDMO projects - High Capex Intensity - High val
56%
- High Capex Intensity - High value CDMO project deliveries and ramp-up of new assets 54% 56% 1.1x * Covid led demand increase and De-stocking FY20 Gross margins Asset turnover FY23 0.77
1.1x
gh Capex Intensity - High value CDMO project deliveries and ramp-up of new assets 54% 56% 1.1x * Covid led demand increase and De-stocking FY20 Gross margins Asset turnover FY23 0.77x Mid
Advertisement
← All transcriptsLAURUSLABS stock page →